Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Raised Intraocular Pressure Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Assessment of Visual Function in Ophthalmic Disorders Using Virtual Visual Field Analysis

NCT04110015
View directory record Official record
Conditions
Visual Pathway Disorder, Glaucoma, Retinal Disease
Interventions
virtual visual field
Device
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01291108
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-210669, bimatoprost, bimatoprost vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
25
States / cities
Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 10, 2026, 5:49 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Know Your Pressures NYC

NCT05992415
View directory record Official record
Conditions
Glaucoma, Hypertension, Glaucoma, Suspect, Elevated Blood Pressure
Interventions
Virtual Automated Navigator Intervention with Health Education, Usual Care
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
7,085 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

NCT02102750
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Preservative free tafluprost opthalmic solution
Drug
Lead sponsor
Santen Oy
Industry
Eligibility
1 Month to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Nov 10, 2026, 5:49 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Critical Flicker Fusion Versus Automated Visual Fields in the Detection of Early Glaucoma

NCT01076114
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
East Meadow, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Nov 10, 2026, 5:49 PM EST
Active, not recruiting Not applicable Interventional

Electrical Stimulation for the Treatment of Optic Neuropathies

NCT05626426
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 2 Interventional Results available

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

NCT02754596
View directory record Official record
Conditions
Glaucoma Open-angle
Interventions
Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 10, 2026, 5:49 PM EST
Completed No phase listed Observational Results available

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

NCT03868254
View directory record Official record
Conditions
Glaucoma
Interventions
XEN Group, Phacoemulsification
Device · Procedure
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 10, 2026, 5:49 PM EST
Recruiting Phase 2 Interventional

A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.

NCT07913074
View directory record Official record
Conditions
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5%, Timolol 0.05% eye drops
Drug
Lead sponsor
Tavo Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Glendale, California • Newport Beach, California • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 10, 2026, 5:49 PM EST
Terminated Not applicable Interventional Results available

The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)

NCT02691455
View directory record Official record
Conditions
Glaucoma
Interventions
Baerveldt Glaucoma Implant 350-mm2 / BG101-350, Transscleral Diode Laser Cyclophotocoagulation, Ahmed Model FP7 Flexible Plate, Baerveldt Glaucoma Implant 250-mm2 / BG103-250
Device · Procedure
Lead sponsor
Robert Feldman
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Nov 10, 2026, 5:49 PM EST
Recruiting Not applicable Interventional

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

NCT05844384
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Nanodropper, Regular dropper
Device
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 10, 2026, 5:49 PM EST
Completed No phase listed Observational

Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients

NCT05654493
View directory record Official record
Conditions
Glaucoma
Interventions
MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 10, 2026, 5:49 PM EST
Completed Not applicable Interventional

Technology-based Eye Care Services (TECS) Compare

NCT02558712
View directory record Official record
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Nov 10, 2026, 5:49 PM EST
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 10, 2026, 5:49 PM EST
Terminated No phase listed Observational

An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation

NCT01719809
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 2 Interventional Results available

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01707381
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
BOL-303259-X, Timolol maleate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Nov 10, 2026, 5:49 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Ultrasonic Evaluation of Ocular Tissues

NCT00279695
View directory record Official record
Conditions
Glaucoma, Tumors, Age-Related Macular Degeneration
Interventions
high frequency ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 2 Interventional

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

NCT01474135
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Inglewood, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Nov 10, 2026, 5:49 PM EST
Completed Not applicable Interventional

Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree

NCT06851546
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Nasal 180° Selective Laser Trabeculoplasty (SLT), Inferior 180° Selective Laser Trabeculoplasty (SLT)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 10, 2026, 5:49 PM EST
Completed Phase 3 Interventional Results available

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04285580
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, LUMIGAN
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Nov 10, 2026, 5:49 PM EST
Completed Not applicable Interventional Results available

Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light Perceived

NCT03469297
View directory record Official record
Conditions
Glaucoma
Interventions
Brown Glaucoma Implant
Device
Lead sponsor
MicroOptx
Industry
Eligibility
22 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Bloomington, Minnesota • Dayton, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Nov 10, 2026, 5:49 PM EST